U

United Therapeutics Corporation

Biotech company develops PAH therapies

National Transplant Accounts Director

Full-Time
$158k - $210k/yr
Expert
Bachelor's, Master's
Remote in USA
RemoteHome-based anywhere in the Continental US; requires 60% national travel.
Sales & Account ManagementAccount Management

About the job

Requirements
  • A bachelor's degree in a related field, or a master's degree with the corresponding experience requirements.
  • At least 10 years of relevant experience in organ operations or healthcare services focused on payer access, reimbursement, and stakeholder engagement with a bachelor's degree, or at least 8 years with a master's degree.
  • At least 5 years of related transplant administration experience, including managed care, marketing, and business case development with a bachelor's degree, or at least 3 years with a master's degree.
  • Executive-level business presentation experience.
  • Ability to cultivate strong business relationships and communicate clinical and technical information.
  • Expertise in transplant reimbursement dynamics, including Medicare cost reporting and payer contracting.
  • Expertise in access and reimbursement, including payer policies and processes.
  • Ability to gather and interpret data for executive leadership.
  • Understanding of Organ Procurement Organization organ acquisition charges and reimbursement processes.
  • Proficiency with Microsoft Office Suite, including Outlook, Excel, PowerPoint, and Word.
  • Ability to interact with other departments and prioritize tasks.
  • Ability to build and maintain positive working relationships with payer stakeholders to ensure access and reimbursement for current and future Lung Bioengineering services and products.
Responsibilities
  • Establish and maintain relationships with transplant administration, relevant key opinion leader payer stakeholders, and transplant benefit networks; cultivate business opportunities and implement action plans aligned with brand strategy and payer objectives.
  • Network to identify key contacts and opportunities, and develop, pitch, and implement business opportunities with transplant leadership to expand access and advance organizational objectives.
  • Negotiate transplant center and Organ Procurement Organization contracts within leadership guidance and finance and legal parameters; collaborate with health systems, transplant finance, and legal throughout contracting from introduction through execution, and manage contract amendments.
  • Provide reimbursement and coverage expertise and educate transplant centers, administrators, and providers on commercial services, products, and reimbursement processes to address access challenges.
  • Create and maintain accurate customer data in customer relationship management and SAP systems, serve as the primary internal invoicing contact for finance, and support operational processes.
  • Conduct regular meetings with transplant hospital stakeholders about business cases, performance progress, opportunities, competitive dynamics, and training needs.
  • Develop and execute strategic plans, goals, and objectives; prepare and deliver formal business and product presentations to payers; and enhance device and product access and coverage.
  • Partner with Liaisons as a primary resource for physician and process opportunities to support healthcare professional engagement, process development, education, and coordination related to transplant center and Organ Procurement Organization contracting.
  • Partner with Payer Account Directors as the primary resource for managed markets opportunities and issues, educate on managed care concepts, and engage Market Access senior management to exchange payer and transplant management perspectives.
  • Collaborate with field health economics and outcomes research teams as needed to support medical presentations of clinical and economic information to payers and transplant administrators.
  • Work directly with transplant administrators to address access and reimbursement challenges and provide education and resources for navigating coverage and payment processes.
  • Represent Lung Bioengineering at local, regional, and national meetings to advance lung transplantation, organ donation best practices, and preservation technologies.
  • Work cross-functionally with Liaisons, Clinical Services, health economics and outcomes research, Patient Advocacy, NADs, Marketing, Legal, and Compliance to implement aligned payer initiatives and coordinated execution.
  • Manage relationships with Transplant Administration Organizations.
  • Monitor and report key developments and trends across assigned accounts and geographies, and develop and deliver presentations to senior management on transplant trends, market dynamics, utilization, and financial metrics.
  • Provide planning, data interpretation, and insights to support relationship management and business decisions.
  • Perform other duties as assigned.
Desired Qualifications
  • A master's degree in a related field.
  • At least 2 years of experience navigating the national payer landscape.
  • Current relationships with relevant managed care organizations.

About the company

U

United Therapeutics Corporation

View

United Therapeutics develops therapies for life-threatening diseases, with a focus on pulmonary arterial hypertension and rare conditions. Its approved medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, treat PAH and pediatric neuroblastoma and are delivered by injections, inhalations, or oral tablets. The company also pursues regenerative medicine and xenotransplantation through its Lung Biotechnology PBC and Revivicor units to create bioengineered organs for transplant. It differentiates itself by combining drug development with organ engineering and by operating as a Public Benefit Corporation that balances profits with social and environmental goals, aiming to extend lives and increase access to transplantable organs.

Company Size

N/A

Company Stage

IPO

Headquarters

Silver Spring, Maryland

Founded

1996

Get referred to United Therapeutics Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA accepted ralinepag NDA August 2026 and nebulized Tyvaso sNDA September 2026.
  • Q2 2026 net income rose to $333 million; buybacks retired 5.84% shares.
  • Phase 3 ADVANCE OUTCOMES and TETON showed improvement across PAH and IPF programs.

What critics are saying

  • Q2 2026 revenue fell 2%; Tyvaso sales dropped, exposing heavy product concentration.
  • Liquidia’s appeals and labeling fights can still blunt Treprostinil economics by 2027.
  • If ralinepag and IPF filings disappoint FDA, United Therapeutics remains a single-portfolio biotech.

What makes United Therapeutics Corporation unique

  • Martine Rothblatt built United Therapeutics around PAH drugs plus xenotransplantation, with three operating organ sites.
  • September 2026 Delaware ruling strengthened its treprostinil patent moat against Liquidia’s Yutrepia.
  • Stewartville’s August 12, 2026 DPF facility expands gene-edited pig organ production capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Time Off
  • Paid Holidays
  • Paid Vacation
  • Parental Leave

Company News

Associated Press
Oct 20th, 2026
United Therapeutics opens third pathogen-free xenograft facility in Houston to scale organ production

United Therapeutics has opened its third Designated Pathogen-Free (DPF) facility, in Houston, Texas. The site produces xenografts, which are animal organs for transplant into humans. The first facility opened in Christiansburg, Virginia, in 2024 to supply clinical trials. The second opened in Stewartville, Minnesota, on August 12, 2026. The Houston and Stewartville sites are built to scale commercial production if regulators approve the products. The facilities use air and water filtration, filtered feed, and decontamination entryways to keep out pathogens. Solar arrays offset a significant part of their energy use. "Every day, people with end-stage organ disease die waiting for an organ that never comes," said chief executive officer Martine Rothblatt. The products remain investigational and are not approved anywhere.

Yahoo Finance
Oct 16th, 2026
Two cash-rich stocks to watch, United Therapeutics and Core Natural Resources, and one to avoid

StockStory has named two cash-generating stocks to watch and one to avoid, arguing that strong cash flow alone does not guarantee good returns. It passes on Simply Good Foods, the maker of Atkins products. Revenue grew 5.2% annually over three years, sales are estimated to fall 9.9% in the next 12 months, and operating margin dropped 31.9 percentage points. The stock trades at $11.12, or 6.5x forward earnings. United Therapeutics, with a free cash flow margin of 34.6%, grew revenue 14.7% a year over five years and posts a 29.1% return on capital. It trades at $541.55, or 18.3x forward earnings. Core Natural Resources, a coal miner with a 6.1% free cash flow margin, grew revenue 15.6% annually over ten years to $4.27 billion. Its shares cost $89.05, or 20.7x forward earnings.

STAT
Oct 14th, 2026
FDA adcomm members' ties to industry under scrutiny.

FDA adcomm members' ties to industry under scrutiny. The FTC going after Martin Shkreli again, a study on GLP-1s and social outcomes, and more biotech news. Oct. 14, 2026 National Biotech Reporter Good morning. Yesterday, we got the devastating news that STAT's infectious disease correspondent, Helen Branswell, passed away. She was a reporter I always looked up to and was also an incredibly generous colleague. Please take the time to read this tribute to her. The need-to-know this morning. * Liquidia and United Therapeutics reached a settlement agreement that resolves their ongoing patent litigation over Liquidia's treatment for pulmonary arterial hypertension. New trial to test effect of GLP-1s on social outcomes. Researchers in Pittsburgh are launching a novel type of GLP-1 trial - testing not only if the drug will help people with addiction, but also if it will help reduce recidivism while improving other employment, health, and housing outcomes. The Center for Addiction Science, Policy and Research (CASPR), a non-profit organizing the effort, and the Allegheny County Department of Human Services are planning to launch the trial in early 2027. They will enroll up to 1,200 adults with alcohol use disorder, opioid use disorder, or both, who are also at high risk of criminal-justice involvement. Half will be randomly assigned to take Novo Nordisk's Wegovy, according to a press release issued yesterday. Your morning rundown of the science, politics, and money driving biotech today

Associated Press
Oct 13th, 2026
Liquidia to pay $380.7M to end all six lawsuits with United Therapeutics

Liquidia has settled all six lawsuits with United Therapeutics, ensuring patients with pulmonary arterial hypertension can keep using its inhaled drug YUTREPIA. The company will pay a net $380.7 million across 2026 and 2027. The deal follows a September 30, 2026, US District Court ruling that Liquidia infringed a United Therapeutics patent covering treatment of a related lung condition. Liquidia will not appeal and has asked to remove that indication from YUTREPIA's label. Payments include $175 million within 30 business days and $145.4 million in two instalments of $72.7 million, due by January 31, 2027, and April 30, 2027. Liquidia will also pay $60.3 million this month to parties with interests in related antitrust litigation. Liquidia reported preliminary third-quarter YUTREPIA net sales of $222.7 million and $396.1 million in cash as of September 30, 2026. It expects to fund the payments without new financing.

BioPharma Watch
Oct 13th, 2026
United Therapeutics presents new data at the CHEST 2026 Annual Meeting.

United Therapeutics presents new data at the CHEST 2026 Annual Meeting. Key Takeaway: United Therapeutics Corporation announced its participation in the CHEST 2026 Annual Meeting, where it will present two oral and five poster presentations. The event, hosted by the American College of Chest Physicians, will take place from October 18-21, 2026, in Phoenix, Arizona. The company aims to highlight its commercial and development portfolio. Market sentiment analysis. Positive factors. * Presentation of new data at a major conference. * Engagement with the medical community through sponsorship. * Diverse portfolio showcased through multiple presentations. BiopharmaWatch analysis. From its catalyst data and publicly available data · not financial advice Best trade, last catalyst 120-day peak, hindsight Typical move average across 6 past catalysts Lead asset NDA/BLA · Pulmonary Arterial Hypertension SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.-(BUSINESS WIRE)-United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that two oral and five poster presentations will be presented across its commercial and development portfolio at the CHEST 2026 Annual Meeting hosted by the American College of Chest Physicians taking place October 18-21, 2026, in Phoenix, Arizona. United Therapeutics will also sponsor and host Time to Look Closer: Emerging Data and Sc Frequently asked questions. What will United Therapeutics present at CHEST 2026? United Therapeutics will present two oral and five poster presentations. When is the CHEST 2026 Annual Meeting? The CHEST 2026 Annual Meeting will take place from October 18-21, 2026. Where is the CHEST 2026 Annual Meeting held? The meeting will be held in Phoenix, Arizona. Who hosts the CHEST 2026 Annual Meeting? The meeting is hosted by the American College of Chest Physicians.